Breaking News Instant updates and real-time market news.

BHVN

Biohaven Pharmaceutical

$45.32

1.36 (3.09%)

18:14
02/15/19
02/15
18:14
02/15/19
18:14

Biohaven treatment of multiple system atrophy granted FDA orphan designation

According to a post on the FDA's website, Biohaven Pharmaceutical's treatment of multiple system atrophy was granted orphan designation. Reference Link

BHVN Biohaven Pharmaceutical
$45.32

1.36 (3.09%)

02/01/19
PIPR
02/01/19
NO CHANGE
PIPR
Overweight
Amgen acquisition of Alexion could make a lot of sense, says Piper Jaffray
While most investors anticipate Amgen (AMGN) could be shopping for smaller, bolt-on deals amid increased investor and press speculation that it is now an active acquirer, a larger deal with more near-term accretion potential may make more sense, Piper Jaffray analyst Christopher Raymond tells investors in a research note partially titled "Go Big or Go Home?" He thinks a potential Amgen for Alexion Pharmaceuticals (ALXN) deal "could actually make a lot of sense." Even at levels approaching $200 per share for Alexion, Amgen "could make a strong argument for a business combination," says Raymond. Alexion closed yesterday up $1.64 to $122.96. The analyst admits that some "bolt-on deals have been bandied around" by investors that "arguably make sense" for Amgen, including Biohaven Pharmaceutical and Amarin (AMRN). However, none of these options on their own get Amgen "to where they need to be to address the growth challenges of the legacy franchises," Raymond argues. He thinks a better deal for the company may be Alexion, which would bring in a "long-tailed asset" with Soliris/Ultomiris, an area Amgen has already approached with its Soliris biosimilar effort. The analyst's math has the potential deal being accretive next year, growing to 20%-plus accretion by 2024 for Amgen, even at a takeout price approaching $200 per Alexion share. Raymond keeps Overweight ratings on both companies.
12/28/18
OPCO
12/28/18
NO CHANGE
Target $54
OPCO
Outperform
Biohaven price target lowered to $54 from $63 at Oppenheimer
Oppenheimer analyst Esther Rajavelu lowered her price target for Biohaven Pharmaceutical to $54 from $63 while maintaining an Outperform rating on the shares. The analyst updated her model to reflect the company's weighted average cost of capital as well as well as the impact of its $144M equity raise. Rajavelu continues to believe Biohaven's glutamate platform, with two late-stage assets, is "under-the-radar."
12/10/18
PIPR
12/10/18
NO CHANGE
Target $65
PIPR
Overweight
Biohaven's rimegepant 'definitively' safe, well tolerated, says Piper Jaffray
Biohaven Pharmaceutical this morning reported positive data from a 12-month safety study of 1,780 patients, which included regularly scheduled liver function tests, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The bottom line is that rimegepant now definitively appears to be a safe and well-tolerated treatment and that Biohaven has successfully engineered out the liver toxicity associated with the first generation oral calcitonin gene-related peptides, says the analyst. He adds rimegepant also demonstrated efficacy in prevention, which he thinks bodes well for the ongoing pivotal trial. Van Buren reiterates an Overweight rating on Biohaven Pharmaceutical with a $65 price target.
12/03/18
PIPR
12/03/18
NO CHANGE
Target $65
PIPR
Overweight
Piper says buy Biohaven 'aggressively' after 'impressive' data
Biohaven Pharmaceutical (BHVN) this morning reported "impressive" topline data from the Phase III trial testing the Zydis orally dissolving tablet formulation of rimegepant, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The study not only achieved statistical significance on both co-primary endpoints, "but surprisingly" also demonstrated an "incredibly rapid" 15 minute onset of action, says the analyst. Further, he notes that Biohaven reported pooled safety data from what is now three Phase III rimegepant studies and that the candidate "continues to be safe and well tolerated" with no signal of liver toxicity. Van Buren believes the new data "definitely makes" rimegepant a superior product to Allergan's (AGN) ubrogepant and the "best-in-class" oral calcitonin gene-related peptide. He reiterates an Overweight rating on Biohaven with a $65 price target and recommends that investors buy the stock "aggressively."

TODAY'S FREE FLY STORIES

CAL

Caleres

$25.72

-0.11 (-0.43%)

15:34
03/21/19
03/21
15:34
03/21/19
15:34
Options
Caleres options imply 11.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

CURLF

Curaleaf Holdings

$0.00

(0.00%)

, CVS

CVS Health

$57.28

1.11 (1.98%)

15:28
03/21/19
03/21
15:28
03/21/19
15:28
Hot Stocks
Curaleaf Holdings spikes 22% after report of CBD products pact with CVS »

Shares of Curaleaf…

CURLF

Curaleaf Holdings

$0.00

(0.00%)

CVS

CVS Health

$57.28

1.11 (1.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

LYG

Lloyds Banking

$3.27

-0.115 (-3.40%)

15:27
03/21/19
03/21
15:27
03/21/19
15:27
Options
Puts lead calls 140:1 in Lloyds Banking as shares underperform sector »

Puts lead calls 140:1 in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IVZ

Invesco

$19.88

0.16 (0.81%)

15:21
03/21/19
03/21
15:21
03/21/19
15:21
Conference/Events
Invesco management to meet with Morgan Stanley »

Meeting to be held In New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 28

    Mar

BV

BrightView

$15.34

-0.23 (-1.48%)

15:20
03/21/19
03/21
15:20
03/21/19
15:20
Hot Stocks
BrightView under investigation for potential securities laws violations »

Thornton Law Firm…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

XHB

SPDR Homebuilders

$38.38

0.82 (2.18%)

15:20
03/21/19
03/21
15:20
03/21/19
15:20
Options
Aggressive call buying in SPDR Homebuilders Fund as the sector sees strength »

Aggressive call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:20
03/21/19
03/21
15:20
03/21/19
15:20
General news
Canada CPI preview »

Canada CPI preview:…

15:20
03/21/19
03/21
15:20
03/21/19
15:20
General news
Canada retail sales preview »

Canada retail sales…

DLAKY

Lufthansa

$0.00

(0.00%)

15:19
03/21/19
03/21
15:19
03/21/19
15:19
Conference/Events
Lufthansa management to meet with Morgan Stanley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

JEF

Jefferies Financial Group

$19.35

0.04 (0.21%)

15:19
03/21/19
03/21
15:19
03/21/19
15:19
Options
Jefferies Financial Group options imply 4.0% move in share price post-earnings, below median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

NEXA

Nexa Resources

$12.46

-0.22 (-1.74%)

15:17
03/21/19
03/21
15:17
03/21/19
15:17
Conference/Events
Nexa Resources management to meet with Morgan Stanley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
03/21/19
03/21
15:17
03/21/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
03/21/19
03/21
15:16
03/21/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:15
03/21/19
03/21
15:15
03/21/19
15:15
General news
Canada CPI preview »

Canada CPI preview:…

SPY

SPDR S&P 500 ETF Trust

$284.73

3.29 (1.17%)

, SPX

S&P 500

$0.00

(0.00%)

15:14
03/21/19
03/21
15:14
03/21/19
15:14
Periodicals
DoubleLine's Gundlach surprised by Fed's dovish double-down, CNBC says »

DoubleLine Capital CEO…

SPY

SPDR S&P 500 ETF Trust

$284.73

3.29 (1.17%)

SPX

S&P 500

$0.00

(0.00%)

QQQ

Invesco QQQ Trust

$182.53

2.79 (1.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRI

Thomson Reuters

$57.40

0.64 (1.13%)

15:12
03/21/19
03/21
15:12
03/21/19
15:12
Conference/Events
Thomson Reuters management to meet with Morgan Stanley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

15:10
03/21/19
03/21
15:10
03/21/19
15:10
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

USB

U.S. Bancorp

$49.78

-0.59 (-1.17%)

, WFC

Wells Fargo

$49.91

-0.48 (-0.95%)

15:06
03/21/19
03/21
15:06
03/21/19
15:06
Hot Stocks
Bank stocks sit out rally, mirroring concern for broader economy »

Shares of financial…

USB

U.S. Bancorp

$49.78

-0.59 (-1.17%)

WFC

Wells Fargo

$49.91

-0.48 (-0.95%)

MS

Morgan Stanley

$43.45

0.425 (0.99%)

JPM

JPMorgan

$102.96

-1.58 (-1.51%)

C

Citi

$64.24

-0.05 (-0.08%)

GS

Goldman Sachs

$195.08

0.81 (0.42%)

BAC

Bank of America

$28.33

-0.3 (-1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

  • 12

    Apr

  • 12

    Apr

  • 15

    Apr

  • 16

    Apr

  • 16

    Apr

  • 17

    Apr

  • 23

    Apr

  • 24

    Apr

  • 28

    May

  • 13

    Jul

  • 13

    Jul

  • 12

    Oct

ZUO

Zuora

$24.08

0.36 (1.52%)

15:04
03/21/19
03/21
15:04
03/21/19
15:04
Options
Zuora options imply 16.5% move in share price post-earnings, below median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 23

    Apr

SMG

Scotts Miracle-Gro

$79.39

2.27 (2.94%)

15:02
03/21/19
03/21
15:02
03/21/19
15:02
Hot Stocks
Scotts Miracle-Gro extends partnership with Major League Baseball »

The Scotts Company and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

BA

Boeing

$374.14

-2.27 (-0.60%)

15:00
03/21/19
03/21
15:00
03/21/19
15:00
Periodicals
Boeing to slow work on 737 planes for 3 days next week, Bloomberg reports »

In an emailed statement…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 28

    May

DRI

Darden

$116.09

7.47 (6.88%)

, BLMN

Bloomin' Brands

$19.73

0.37 (1.91%)

14:54
03/21/19
03/21
14:54
03/21/19
14:54
Upgrade
Darden, Bloomin' Brands rating change at Gordon Haskett »

Darden upgraded to Hold…

DRI

Darden

$116.09

7.47 (6.88%)

BLMN

Bloomin' Brands

$19.73

0.37 (1.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

NSA

National Storage

$28.29

0.5 (1.80%)

14:54
03/21/19
03/21
14:54
03/21/19
14:54
Conference/Events
National Storage management to meet with Morgan Stanley »

Luncheon Meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

AZO

AutoZone

$999.06

17.86 (1.82%)

14:51
03/21/19
03/21
14:51
03/21/19
14:51
Conference/Events
AutoZone management to meet with Morgan Stanley »

Group Dinner Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 26

    Mar

XLK

Technology Select Sector SPDR

$75.09

1.85 (2.53%)

14:50
03/21/19
03/21
14:50
03/21/19
14:50
Options
Timely call buy in SPDR Technology Fund »

Timely call buy in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.